8-K: Microbot's LIBERTY System Gains Traction at ISET Conference

Microbot Medical's LIBERTY Endovascular Robotic System was prominently featured at the International Symposium on Endovascular Therapy (ISET) conference, highlighting its commercial traction and future role.

Summary

• Microbot Medical Inc. announced that its LIBERTY Endovascular Robotic System was featured at the International Symposium on Endovascular Therapy (ISET) conference, held from February 9-12, 2026, in Miami Beach, Florida.
• The LIBERTY System was highlighted during a Town Hall session titled 'Advances in Endovascular Robotics: Will There be a Role in the Future?', which included leading interventional radiologists, cardiologists, and vascular surgeons.
• The discussion focused on the future of single-use handheld vascular robots, specifically emphasizing the LIBERTY System's seamless workflow integration and features.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
• The Company commenced a limited market release (LMR) of the LIBERTY system in late 2025 and plans for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, indicating growing market acceptance and validation for Microbot Medical's flagship product. The increased visibility and reported commercial traction are favorable for a commercial-stage company, though it's not a financial results announcement.

Positives

• The LIBERTY Endovascular Robotic System was featured at a leading vascular disease management conference (ISET), increasing its visibility among key opinion leaders.
• The system was discussed prominently, highlighting its seamless workflow integration and features, which the Company believes are key drivers for broader adoption.
• LIBERTY is gaining commercial traction and exposure as part of its Limited Market Release (LMR) in the US.
• The system has been used across multiple hospitals for a wide range of procedure types, including complex cases.
• Increased interest from physicians across several specialties (interventional radiology, interventional oncology, vascular surgery, interventional cardiology) reinforces its broad clinical relevance and expanding commercial opportunity.
• LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, offering a unique market position.

Risks

• Market conditions may impact the commercialization of the LIBERTY Endovascular Robotic System.
• Risks are inherent in the development of future versions of or applications for the system.
• Uncertainty exists in the results of regulatory pathways and regulatory approvals.
• Political, social, and geopolitical conditions, particularly changes in personnel or processes at the FDA, could pose risks.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries are a risk.
• Maintenance of intellectual property rights is crucial and subject to risk.

Future Outlook

The Company anticipates that the LIBERTY System's seamless workflow integration and features will be key drivers for broader adoption, shaping the next phase of peripheral endovascular intervention. They plan for a full market release at the Society of Interventional Radiology (SIR) conference in April 2026, aiming to deepen market adoption.

Management Comments

• "ISET plays a meaningful role in shaping the future of endovascular innovation, providing a platform where healthcare leadership and emerging technologies converge. We believe that LIBERTYs inclusion in this important dialogue confirms the commercial traction of LIBERTY and reinforces our position among a prestigious group of interventional radiologists, vascular surgeons and other clinical decision makers."
• "To date, LIBERTY has been used across multiple hospitals for a wide range of procedure types, including complex cases. We have seen increased interest from physicians across several specialties within the same account and network of hospitals, including interventional radiology, interventional oncology, vascular surgery and interventional cardiology, which we believe is reinforcing its broad clinical relevance in the peripheral space and expanding overall commercial opportunity."

Industry Context

StockSavvy.ai notes that the endovascular robotics market is an evolving segment within medical devices, driven by the need for enhanced precision, reduced radiation exposure, and improved ergonomics for clinicians. Microbot Medical's participation and prominent feature at ISET, a key industry conference, positions LIBERTY as a significant contender, especially given its unique FDA-cleared single-use, remotely operated status. This aligns with broader industry trends towards minimally invasive procedures and robotic assistance in complex interventions.

Comparison to Industry Standards

• LIBERTY is highlighted as the only FDA cleared, single-use endovascular robotic system, differentiating it from multi-use or non-FDA cleared robotic platforms in the market.
• The system's focus on reducing radiation exposure and physical strain addresses critical concerns for clinicians, potentially offering a competitive advantage over traditional manual techniques or less advanced robotic systems.
• The reported increased interest from multiple specialties (interventional radiology, interventional oncology, vascular surgery, interventional cardiology) suggests a broader applicability compared to systems focused on a single specialty.

Stakeholder Impact

• Shareholders: Potential for increased valuation due to enhanced market visibility, commercial traction, and future adoption of the LIBERTY system.
• Customers (Hospitals/Clinicians): Access to an FDA-cleared, single-use robotic system designed to improve precision, reduce radiation exposure, and alleviate physical strain during endovascular procedures.
• Patients: Potential for improved outcomes and safety in peripheral endovascular interventions through advanced robotic assistance.

Next Steps

• Continue the limited market release (LMR) of the LIBERTY system in the US.
• Plan for a full market release of the LIBERTY system at the Society of Interventional Radiology (SIR) conference in April 2026.
• Deepen market adoption following the full market release.

Key Dates

Recommendation

This filing provides a positive operational update regarding market exposure and commercial traction for Microbot Medical's key product. While it reinforces the company's strategic direction and potential for future growth, it does not contain financial results or new material information that would immediately warrant a 'buy' or 'sell' recommendation. The 'hold' recommendation reflects the positive progress in commercialization and market validation, suggesting continued monitoring of the full market release and subsequent financial performance.

Keywords

Endovascular Robotic System, LIBERTY System, Microbot Medical, ISET conference, FDA cleared, Medical Device, Robotic Surgery, Vascular Disease Management, Peripheral Endovascular Procedures, Commercialization, Limited Market Release